Jazz Pharmaceuticals’ Sunosi (solriamfetol) Receives FDA’s Approval for the Treatment of Sleep Disorders

 Jazz Pharmaceuticals’ Sunosi (solriamfetol) Receives FDA’s Approval for the Treatment of Sleep Disorders

Jazz Pharmaceuticals’ Sunosi (solriamfetol) Receives FDA’s Approval for the Treatment of Sleep Disorders

Shots:

  • The approval is based on P-III TONES study assessing Sunosi (solriamfetol) vs PBO in 900 patients with excessive daytime sleepiness associated with narcolepsy or Obstructive Sleep Apnea (OSA)
  • The P-III TONES study results: @12wks. improvement in PGIc scale (68-74% receiving 75mg & 78-90% receiving 150mg); improvement in wakefulness (assessed in the maintenance of wakefulness test)
  • Sunosi (75mg & 150mg for narcolepsy) (37.5 mg, 75 mg &150 mg for OSA) is a NDRI inhibitor, developed and commercialized by Jazz (Ex. Asia) and has received FDA’s ODD for narcolepsy in the US

Click here to read full press release/ article | Ref: Jazz Pharmaceuticals  | Image:Cronin Movers Group

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post